Zhi Peng Selected Research

Gastrointestinal Neoplasms (Gastrointestinal Cancer)

1/2022	Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer.
1/2022	Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
11/2021	Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
5/2021	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer.
1/2021	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer.
1/2021	Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
10/2020	The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.
8/2020	Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers.
1/2020	Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.
1/2020	Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhi Peng Research Topics

Disease

37	Neoplasms (Cancer) 10/2022 - 01/2009
23	Stomach Neoplasms (Stomach Cancer) 02/2022 - 01/2014
11	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2022 - 01/2019
8	Colorectal Neoplasms (Colorectal Cancer) 04/2022 - 01/2019
8	Adenocarcinoma 02/2022 - 01/2020
6	Microsatellite Instability 01/2022 - 01/2020
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2020 - 12/2005
5	Leukemia 06/2012 - 01/2004
3	Hypertension (High Blood Pressure) 05/2022 - 01/2022
3	Circulating Neoplastic Cells 10/2021 - 11/2017
3	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 01/2011
3	Melanoma (Melanoma, Malignant) 10/2020 - 03/2019
3	Chronic Hepatitis B 01/2019 - 05/2013
3	Neoplasm Metastasis (Metastasis) 03/2018 - 04/2015
2	Neuroendocrine Carcinoma 01/2022 - 01/2020
2	Hemorrhage 06/2021 - 01/2021
2	Infections 04/2021 - 01/2021
2	Esophageal Neoplasms (Esophageal Cancer) 08/2020 - 01/2013
2	Esophageal Squamous Cell Carcinoma 01/2019 - 01/2015
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 05/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Osteoarthritis 01/2022
1	Epstein-Barr Virus Infections 01/2022
1	Hyperbilirubinemia 01/2022
1	Communicable Diseases (Infectious Diseases) 11/2021
1	Anemia 11/2021
1	Asthenia 11/2021
1	Alopecia (Baldness) 11/2021
1	Developmental Dysplasia of the Hip 09/2021
1	Hypersplenism (Anemia, Splenic) 06/2021
1	Fibrosis (Cirrhosis) 06/2021
1	Magnesium Deficiency (Deficiency, Magnesium) 04/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 04/2021
1	Turcot syndrome 01/2021
1	Wounds and Injuries (Trauma) 01/2021
1	Hypesthesia (Numbness) 01/2021
1	Leukopenia 01/2021
1	Neutropenia 01/2021
1	Surgical Wound Infection 01/2021
1	Thrombosis (Thrombus) 01/2021
1	Varicose Veins (Varicose Vein) 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 10/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2020
1	Carcinoma (Carcinomatosis) 01/2020

Drug/Important Bio-Agent (IBA)

19	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2019
16	Biomarkers (Surrogate Marker)IBA 05/2022 - 05/2016
8	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2004
6	Tyrosine Kinase InhibitorsIBA 05/2022 - 09/2014
5	LigandsIBA 08/2020 - 11/2015
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 05/2022 - 01/2021
3	human ERBB2 proteinIBA 04/2022 - 04/2015
3	Messenger RNA (mRNA)IBA 01/2022 - 06/2011
3	HMPL-013IBA 01/2022 - 02/2020
3	regorafenibIBA 01/2022 - 02/2020
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2017 - 11/2004
3	Trastuzumab (Herceptin)FDA Link 05/2016 - 09/2015
2	B7-H1 AntigenIBA 05/2022 - 01/2020
2	toripalimabIBA 02/2022 - 01/2020
2	BilirubinIBA 02/2022 - 01/2021
2	RNA (Ribonucleic Acid)IBA 11/2021 - 10/2021
2	130-nm albumin-bound paclitaxelIBA 05/2021 - 01/2020
2	Gemcitabine FDA Link 05/2021 - 01/2020
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2013
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 09/2014
2	Tumor Biomarkers (Tumor Markers)IBA 01/2020 - 01/2015
2	ParaffinIBA 11/2015 - 08/2012
2	Antiviral Agents (Antivirals)IBA 06/2014 - 05/2013
2	Imatinib Mesylate (Gleevec)FDA Link 06/2012 - 05/2011
2	Small Interfering RNA (siRNA)IBA 11/2004 - 01/2004
1	Alanine Transaminase (SGPT)IBA 05/2022
1	anlotinibIBA 05/2022
1	Transaminases (Aminotransferases)IBA 02/2022
1	surufatinibIBA 02/2022
1	Dacarbazine (DIC)FDA LinkGeneric 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	HLA-B Antigens (HLA-B)IBA 11/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 11/2021
1	Capsules (Microcapsules)IBA 09/2021
1	MagnesiumIBA 04/2021
1	Circulating Tumor DNAIBA 01/2021
1	pembrolizumabIBA 01/2021
1	camrelizumabIBA 01/2021
1	apatinibIBA 01/2021
1	Capecitabine (Xeloda)FDA Link 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Biological ProductsIBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	PowdersIBA 01/2021
1	Vancomycin FDA LinkGeneric 01/2021
1	trifluridine tipiracil drug combinationIBA 02/2020

Therapy/Procedure

25	Therapeutics 10/2022 - 05/2011
17	Immunotherapy 10/2022 - 07/2019
14	Drug Therapy (Chemotherapy) 04/2022 - 01/2013
1	Topical Administration 01/2021
1	Arthroplasty 01/2021
1	Replacement Arthroplasty 01/2021
1	Knee Replacement Arthroplasty (Total Knee Replacement) 01/2021
1	Neoadjuvant Therapy 01/2021
1	Radiotherapy 08/2020